Shares of Radius Health Inc (NASDAQ:RDUS) have been assigned a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $55.75.
A number of analysts recently commented on RDUS shares. Morgan Stanley boosted their price objective on shares of Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a report on Friday, March 2nd. JPMorgan Chase & Co. reduced their price target on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating on the stock in a report on Monday, February 12th. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Cantor Fitzgerald set a $58.00 price target on shares of Radius Health and gave the company a “buy” rating in a report on Friday, December 15th. Finally, Citigroup began coverage on shares of Radius Health in a report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target on the stock.
Shares of Radius Health (RDUS) opened at $35.28 on Friday. The company has a market cap of $1,489.78, a PE ratio of -6.08 and a beta of 1.19. Radius Health has a fifty-two week low of $24.66 and a fifty-two week high of $49.16. The company has a current ratio of 5.04, a quick ratio of 12.79 and a debt-to-equity ratio of 0.69.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.16). The company had revenue of $7.66 million for the quarter, compared to analysts’ expectations of $7.37 million. The company’s quarterly revenue was up 666.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.22) earnings per share. analysts forecast that Radius Health will post -5.05 EPS for the current year.
In other news, major shareholder Growth N. V. Biotech acquired 80,000 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was acquired at an average price of $32.52 per share, with a total value of $2,601,600.00. Following the completion of the transaction, the insider now directly owns 5,853,799 shares in the company, valued at approximately $190,365,543.48. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech acquired 75,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was purchased at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the transaction, the insider now owns 5,773,799 shares of the company’s stock, valued at $198,503,209.62. The disclosure for this purchase can be found here. 15.00% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of RDUS. Cubist Systematic Strategies LLC acquired a new position in shares of Radius Health in the third quarter valued at approximately $110,000. Jane Street Group LLC raised its position in shares of Radius Health by 24.7% in the fourth quarter. Jane Street Group LLC now owns 10,043 shares of the biopharmaceutical company’s stock valued at $319,000 after buying an additional 1,988 shares during the last quarter. MANA Advisors LLC acquired a new position in shares of Radius Health in the fourth quarter valued at approximately $347,000. Teacher Retirement System of Texas acquired a new position in shares of Radius Health in the fourth quarter valued at approximately $353,000. Finally, Daiwa Securities Group Inc. acquired a new position in shares of Radius Health in the third quarter valued at approximately $385,000.
ILLEGAL ACTIVITY NOTICE: “Radius Health Inc (RDUS) Given Consensus Rating of “Hold” by Brokerages” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/17/radius-health-inc-rdus-given-consensus-rating-of-hold-by-brokerages.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.